In practice, when specialists test for ER or PR status in BC, they look for the presence of ERα and PR (either form), since these receptors influence how well cancer will respond to hormone therapy (HT) such as tamoxifen or aromatase inhibitors (AIs) [11]. Here, CYP19A1 is linked to breast cancer.